ArticlePediatrics2026
Discretionary Child Protective Services Reporting for Infants With Prenatal Opioid Exposure.
Article in Pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveHospital guidelines implemented in May 2021 to end reflexive child protective services (CPS) reporting for infants with prenatal substance exposure nearly halved overall reporting rates among infants with prenatal opioid exposure (IPOE). Given concerns that discretionary reporting may exacerbate inequities, this study assessed whether the guideline's effects differed between subgroups of IPOEs.
methodsWe used a difference-in-difference-in-differences (DDD) approach to assess the differential impact of guideline implementation on rates of CPS reporting and discharge in the custody of a biological parent by minoritized (vs nonminoritized) birthing parent race and ethnicity, prescribed (vs any nonprescribed) opioid exposure, and presence (vs absence) of additional nonopioid coexposures. Analyses included 3581 IPOEs born across 17 Massachusetts birthing hospitals from 2017 to 2024.
resultsIn DDD analyses, guideline implementation did not differentially affect rates of CPS reporting by race and ethnicity or coexposure to cannabis. Guideline implementation did lead to larger decreases in CPS reporting rates among IPOEs exposed to only prescribed opioids compared with those exposed to nonprescribed opioids (DDD, -61.3 percentage points [pp] [95% CI, -65.6 to -57.0]), as well as larger decreases among IPOEs without additional exposures to alcohol (-27.1 pp [-37.0 to -17.2]), amphetamines (-17.7 pp [-27.7 to -7.8]), benzodiazepines (-16.4 pp [-26.4 to -6.4]), and cocaine (-55.5 pp [-64.2 to -46.8]). Guideline implementation had no overall or differential impacts on rates of discharge in parental custody.
conclusionGuideline-informed discretionary reporting for IPOEs did not lead to differential impacts by race or ethnicity. The largest decreases in reporting were among infants with only prescribed opioid exposure and without other substance coexposures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.